Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis.

2.50
Hdl Handle:
http://hdl.handle.net/11287/600306
Title:
Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis.
Authors:
Kennedy, N A; Warner, B; Johnston, E L; Flanders, L; Hendy, P; Ding, N S; Harris, R; Fadra, A S; Basquill, C; Lamb, C A; Cameron, F L; Murray, C D; Parkes, M; Gooding, I; Ahmad, Tariq; Gaya, D R; Mann, S; Lindsay, J O; Gordon, J; Satsangi, J; Hart, A; McCartney, S; Irving, P; Lees, C W
Abstract:
Infliximab and adalimumab have established roles in inflammatory bowel disease (IBD) therapy. UK regulators mandate reassessment after 12 months' anti-TNF therapy for IBD, with consideration of treatment withdrawal. There is a need for more data to establish the relapse rates following treatment cessation.
Citation:
Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. 2016 Apr;43(8):910-923 Aliment. Pharmacol. Ther.
Publisher:
Wiley
Journal:
Alimentary pharmacology & therapeutics
Issue Date:
19-Feb-2016
URI:
http://hdl.handle.net/11287/600306
DOI:
10.1111/apt.13547
PubMed ID:
26892328
Additional Links:
http://dx.doi.org/10.1111/apt.13547
Note:
This article is freely available via Open Access. Click on the 'Additional Link' above to access the full-text from the publisher's site.
Type:
Journal Article; Meta-Analysis; Systematic review
Language:
en
ISSN:
1365-2036
Appears in Collections:
Gastroenterology; 2016 RD&E publications

Full metadata record

DC FieldValue Language
dc.contributor.authorKennedy, N Aen
dc.contributor.authorWarner, Ben
dc.contributor.authorJohnston, E Len
dc.contributor.authorFlanders, Len
dc.contributor.authorHendy, Pen
dc.contributor.authorDing, N Sen
dc.contributor.authorHarris, Ren
dc.contributor.authorFadra, A Sen
dc.contributor.authorBasquill, Cen
dc.contributor.authorLamb, C Aen
dc.contributor.authorCameron, F Len
dc.contributor.authorMurray, C Den
dc.contributor.authorParkes, Men
dc.contributor.authorGooding, Ien
dc.contributor.authorAhmad, Tariqen
dc.contributor.authorGaya, D Ren
dc.contributor.authorMann, Sen
dc.contributor.authorLindsay, J Oen
dc.contributor.authorGordon, Jen
dc.contributor.authorSatsangi, Jen
dc.contributor.authorHart, Aen
dc.contributor.authorMcCartney, Sen
dc.contributor.authorIrving, Pen
dc.contributor.authorLees, C Wen
dc.date.accessioned2016-02-29T11:11:49Zen
dc.date.available2016-02-29T11:11:49Zen
dc.date.issued2016-02-19en
dc.identifier.citationRelapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. 2016 Apr;43(8):910-923 Aliment. Pharmacol. Ther.en
dc.identifier.issn1365-2036en
dc.identifier.pmid26892328en
dc.identifier.doi10.1111/apt.13547en
dc.identifier.urihttp://hdl.handle.net/11287/600306en
dc.description.abstractInfliximab and adalimumab have established roles in inflammatory bowel disease (IBD) therapy. UK regulators mandate reassessment after 12 months' anti-TNF therapy for IBD, with consideration of treatment withdrawal. There is a need for more data to establish the relapse rates following treatment cessation.en
dc.languageENGen
dc.language.isoenen
dc.publisherWileyen
dc.relation.urlhttp://dx.doi.org/10.1111/apt.13547en
dc.rightsArchived with thanks to Alimentary Pharmacology & Therapeutics. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.en
dc.subjectWessex Classification Subject Headings::Gastroenterologyen
dc.titleRelapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis.en
dc.typeJournal Articleen
dc.typeMeta-Analysisen
dc.typeSystematic reviewen
dc.identifier.journalAlimentary pharmacology & therapeuticsen
dc.description.noteThis article is freely available via Open Access. Click on the 'Additional Link' above to access the full-text from the publisher's site.en
dc.type.versionIn press (epub ahead of print)en

Related articles on PubMed

All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.